Clinical Impact of TROPION-Breast02: Defining the Role of Datopotamab Deruxtecan in Metastatic TNBC

The TROPION-Breast02 trial provides important evidence supporting the role of datopotamab deruxtecan in the treatment of metastatic triple-negative breast cancer (TNBC). Key findings from this study highlight meaningful clinical activity, including durable responses and a demonstrated overall survival benefit, positioning this agent as a compelling option in later-line settings. Comparing response duration across trials such as ASCENT offers valuable context for understanding how different TROP-2–targeted ADCs may perform in real-world practice. However, limitations related to study design, patient selection, and evolving standards of care must be considered, particularly given the increasing use of pembrolizumab plus chemotherapy in early-stage TNBC. These factors may influence the generalizability of trial results. Emerging real-world evidence helps validate these findings and informs patient selection, especially for those most likely to benefit from ADC therapy.